prophylact
therapeut
vaccin
viral
infect
advanc
recent
year
attenu
live
vaccin
subunitbas
vaccin
ideal
prophylact
vaccin
mimic
natur
immun
induc
infect
gener
longlast
adapt
immun
complement
subunit
vaccin
primarili
target
antibodi
respons
differ
methodolog
investig
develop
vaccin
capabl
drive
cellular
immun
tcell
epitop
discoveri
central
concept
review
signific
tcell
epitopebas
vaccin
prophylact
therapeut
applic
discuss
addit
methodolog
discoveri
tcell
epitop
well
recent
develop
clinic
test
vaccin
variou
viral
infect
explain
inde
epitop
associ
mhc
class
molecul
repres
minim
immunogen
region
protein
antigen
allow
precis
direct
cellular
immun
respons
consid
prophylact
vaccin
applic
tcell
epitopebas
vaccin
may
also
high
impact
therapeut
vaccin
field
combat
chronic
viral
infect
hpv
hcv
hbv
hiv
review
discuss
import
cellular
immun
respons
control
clearanc
viral
infect
well
advantag
limit
tcell
epitopebas
vaccin
addit
method
avail
tcell
epitop
discoveri
updat
development
statu
sever
epitopebas
vaccin
viral
pathogen
discuss
current
envelop
glycoproteinbas
subunit
vaccin
potent
establish
strong
humor
immun
respons
neutral
viral
particl
howev
mani
poor
drive
longlast
cellular
immun
due
lack
intern
viral
protein
gener
tcell
epitop
essenti
elimin
virusinfect
cell
instanc
cellmedi
immun
elicit
mhc
class
irestrict
cytotox
lymphocyt
ctl
play
central
role
control
influenza
viru
infect
inde
cellmedi
respons
gener
primari
influenza
infect
provid
substanti
protect
serolog
distinct
virus
due
recognit
crossreact
epitop
often
intern
viral
protein
conserv
viral
subtyp
theori
also
appli
dengu
viru
denv
antibodi
denv
infect
neutral
protect
particular
serotyp
exposur
anoth
strain
increas
risk
dengu
hemorrhag
fever
dhf
dengu
shock
syndrom
suggest
due
antibodydepend
enhanc
ade
mediat
fc
receptor
activ
macrophag
gwinn
et
al
found
patient
vaccin
denv
vaccin
gener
cellmedi
immun
measur
releas
vaccinestimul
peripher
blood
mononuclear
cell
indirect
evid
suggest
cell
contribut
protect
upregul
ctl
destroy
virusinfect
cell
earli
infect
therefor
limit
diseaseassoci
symptom
suggest
ctl
epitop
vaccin
complement
multival
antibodyproduc
vaccin
best
option
denv
immun
elicit
multipl
serotypespecif
antibodi
respons
addit
crossreact
protect
tcell
respons
regard
chronic
viral
infect
hbv
demonstr
patient
recov
fulli
display
strong
tcell
respons
hbv
nucleocapsid
polymeras
envelop
protein
chronic
hbvinfect
patient
howev
display
poor
tcell
respons
spite
high
viral
antigen
load
specif
chronic
hepat
b
patient
typic
lack
effect
hbvspecif
cellular
immun
defin
function
alter
toleranceanergi
absenc
hbvspecif
cell
unlik
acut
infect
cytokin
product
usual
lower
chronic
infect
addit
ctl
respons
equal
intens
observ
chronic
patient
resolv
infect
spontan
compar
found
acut
patient
recov
fulli
respond
treatment
antivir
tcell
respons
although
benefici
necessari
erad
infect
cell
bodi
shown
detriment
host
sever
instanc
immunopathogenesi
due
andor
tcell
activ
occur
mani
viral
infect
hbv
dengu
inde
cytokin
secret
activ
cell
drive
diseas
phenotyp
acut
phase
viral
hepat
regard
denv
cell
implic
immunopatholog
diseas
associ
secondari
infect
differ
serotyp
therefor
possibl
dhf
dengu
shock
syndrom
sole
mediat
ade
describ
upon
reinfect
new
serotyp
preexist
heterotyp
immun
serotyp
crossreact
drive
partial
memori
respons
known
origin
antigen
sin
alter
immun
respons
skew
low
avid
memori
previou
infect
lead
delay
viral
clearanc
inadequ
kill
virusinfect
cell
note
sever
secondari
infect
associ
increas
inflammatori
cytokin
increas
viral
burden
seem
downward
spiral
dhf
could
mediat
increas
antigen
drive
upregul
inflammatori
cytokin
demonstr
increas
vascular
permeabl
similar
fashion
denv
influenza
viru
clearanc
also
depend
tcell
respons
howev
mechan
lead
lung
immunopatholog
sever
diseas
mention
inflammatori
cytokin
excess
damag
surround
tissu
addit
studi
suggest
role
costimul
influenzaassoci
lung
injuri
therefor
must
understood
cell
necessari
effici
viral
clearanc
destruct
improperli
activ
rational
prophylact
vaccin
viral
infect
begin
knowledg
natur
infect
protect
exogen
reinfect
natur
infect
induc
innat
adapt
immun
respons
figur
innat
immun
respons
nonspecif
essenti
immedi
control
spread
viru
howev
adapt
immun
respons
develop
within
day
character
antibodi
respons
viral
envelop
protein
tcell
respons
viral
epitop
present
mhc
molecul
infect
cell
immun
respons
pathway
innat
adapt
work
perfectli
viru
clear
immun
system
develop
memori
respons
reactiv
host
encount
viru
immun
memori
effici
develop
could
protect
host
lifetim
ideal
vaccin
viru
must
induc
longlast
immun
memori
form
antibodi
product
neutral
free
viru
well
ctl
respons
need
kill
virusinfect
cell
acut
viral
infect
activ
adapt
immun
trigger
viral
antigenspecif
antibodi
ctl
respons
elimin
circul
viru
virusinfect
cell
process
gener
memori
popul
b
cell
reactiv
upon
exposur
new
infect
similarli
ideal
vaccin
includ
compon
viral
antigen
stimul
humor
cellmedi
immun
memori
capabl
protect
host
upon
primari
secondari
infect
current
success
vaccin
possess
qualiti
drive
strong
memoryinduc
humor
respons
import
note
howev
helper
respons
gener
requir
develop
longlast
bcell
immun
therefor
current
antivir
prophylact
vaccin
success
gener
respons
virus
subvert
immun
respons
standard
antibodyinduc
attenu
vaccin
suffici
exampl
denv
typic
elicit
weak
neutral
antibodi
respons
upon
secondari
infect
lead
ade
virus
influenza
antibodi
respons
quit
protect
howev
viru
mutat
quickli
util
antigen
drift
antigen
shift
thu
allow
secondari
infect
evad
exist
immun
chronic
viral
infect
option
restor
function
virusspecif
cell
plausibl
therapeut
vaccin
may
howev
irrelev
restor
bcell
function
product
neutral
antibodi
specif
chronic
virus
latent
within
infect
cell
leav
cytotox
kill
option
erad
virusinfect
cell
ultim
promis
vaccin
candid
may
come
combin
antigen
subunit
tand
bcell
immun
base
anim
model
human
studi
combin
possibl
tand
bcell
ligand
formul
activ
synthet
vaccin
make
sens
concept
would
also
especi
promis
therapeut
vaccin
type
vaccin
would
necessari
drive
tcell
immun
elimin
infect
cell
left
bodi
acut
infect
chronic
viral
infect
hiv
hcv
hbv
desper
need
vaccin
would
clear
linger
virusinfect
cell
success
current
antibodyinduc
hbv
prophylact
vaccin
meant
need
therapeut
vaccin
chronic
diseas
remain
number
antihbv
therapeut
vaccin
approach
evalu
clinic
includ
recombin
antihbv
vaccin
lipopeptidebas
vaccin
dna
vaccin
without
immunomodulatori
drug
review
although
immunotherapi
base
differ
vaccin
formul
demonstr
effici
tcell
respons
healthi
subject
prophylaxi
approach
stimul
transient
clinic
respons
patient
chronic
infect
hbv
although
divers
infect
patient
popul
may
contribut
variabl
efficaci
observ
vaccin
studi
major
unresolv
issu
involv
composit
vaccin
includ
relev
antigen
present
infect
cell
vivo
adjuv
bia
immun
respons
toward
profil
capabl
break
toler
chronic
patient
addit
vaccin
deliveri
system
protect
vaccin
degrad
well
target
facilit
uptak
antigen
adjuv
apc
consid
tcell
vaccin
much
potenti
develop
therapeut
vaccin
chronic
viral
infect
univers
prophylact
vaccin
ideal
epitopebas
vaccin
formul
adjuv
drive
strong
immun
respons
high
immunogen
offer
flexibl
simpl
way
synthes
vaccin
mhc
class
ii
epitop
elicit
helper
respons
necessari
order
get
protect
tcell
memori
end
univers
mhc
class
ii
epitop
span
entir
allel
rang
global
popul
use
inde
mani
studi
demonstr
broad
activ
respons
sever
panmhc
class
ii
epitop
mhc
class
epitop
howev
antigenspecif
viru
target
analysi
memori
ctl
repertoir
clonal
level
human
peripher
blood
mononuclear
cell
reveal
broad
ctl
respons
epitop
wide
varieti
protein
studi
signific
develop
synthet
vaccin
suggest
clinic
relev
epitop
remain
identifi
character
varieti
novel
candid
target
may
found
among
technic
challeng
identifi
epitop
among
mixtur
mhc
class
iassoci
epitop
extract
virusinfect
cell
origin
pathogenassoci
protein
success
identif
epitop
gener
infect
enabl
identif
conserv
tcell
epitop
crosssearch
genom
databas
relat
virus
use
develop
vaccin
famili
virus
genom
proteom
databas
gener
mani
differ
organ
contain
vast
amount
sequenc
data
rel
littl
inform
avail
immunolog
function
major
gene
protein
mhc
class
iassoci
epitop
display
cell
surfac
thought
fingerprint
peptid
reflect
readout
physiolog
statu
cell
identif
peptid
display
cell
infect
viral
pathogen
gener
librari
epitop
genom
databas
search
viral
protein
origin
recogn
process
immun
system
identifi
viral
epitop
protein
associ
adapt
immun
therefor
put
target
crossprotect
vaccin
develop
tcell
epitopebas
vaccin
promis
mani
vaccin
applic
includ
crossserotyp
prophylact
vaccin
well
therapeut
vaccin
therefor
sever
method
exist
sole
purpos
identifi
tcell
epitop
inde
mani
academ
investig
forprofit
compani
implement
method
discuss
product
epitopebas
vaccin
despit
risk
associ
develop
cellular
vaccin
current
exampl
tcell
peptidebas
vaccin
us
fdaapprov
howev
sever
latestag
clinic
trial
display
promis
result
remaind
review
focus
method
use
epitop
discoveri
well
epitopebas
vaccin
current
clinic
trial
commonli
use
method
identif
tcell
epitop
involv
use
overlap
peptid
librari
deriv
protein
interest
use
success
varieti
pathogenassoci
epitop
typic
pool
contain
peptid
nine
amino
acid
length
overlap
degre
ensur
everi
epitop
present
advantag
method
allow
discoveri
mhc
class
ii
epitop
context
sever
allel
rather
test
peptid
individu
peptid
librari
gener
set
matrix
reduc
amount
test
necessari
furthermor
softwar
exist
optim
peptid
pool
use
librari
peptid
use
epitop
determin
addit
methodolog
call
antigen
lead
acquisit
system
atla
use
overlap
peptid
librari
conjunct
ctl
screen
patient
variou
allel
background
patient
divid
analyz
base
whether
immun
protect
overlap
peptid
librari
method
may
abl
identifi
epitop
activ
tcell
respons
still
unabl
uncov
exact
epitop
present
cell
surfac
infect
cell
could
potenti
problemat
protect
epitop
may
necessarili
shape
activ
ctl
present
especi
chronic
diseas
addit
tcell
epitop
identif
taken
motif
predict
epitopemap
algorithm
approach
algorithm
screen
protein
sequenc
nine
ten
amino
acidlong
peptid
segment
predict
bind
one
hla
allel
hla
allel
also
select
maxim
crosshla
coverag
demonstr
epitopebas
vaccin
contain
epitop
restrict
select
hla
supertyp
provid
broadest
possibl
coverag
human
popul
thu
comput
identifi
crossreact
epitop
good
start
point
even
though
extens
immunolog
studi
must
perform
qualifi
epitop
vaccin
candid
although
vast
number
predict
immunolog
character
epitop
report
literatur
immun
epitop
databas
analysi
resourc
iedbar
success
vaccin
base
predict
epitop
yet
develop
clinic
evid
show
predict
analysi
may
reliabl
gener
antigen
natur
process
present
infect
cell
although
motifbas
predict
epitop
may
activ
ctl
vitro
assay
activ
ctl
recogn
natur
process
antigen
peptid
infect
cell
due
differ
motifpredict
epitop
cellular
endogen
present
epitop
antigen
mismatch
inde
subtl
structur
differ
profound
effect
ctl
recognit
vivo
furthermor
data
gener
silico
approach
may
overestim
number
conserv
epitop
may
necessarili
identifi
immunoreact
natur
present
epitop
demonstr
influenza
motifpredict
approach
may
limit
identifi
subdomin
epitop
report
activ
cell
secondari
influenza
virusspecif
respons
furthermor
motifpredict
epitop
valid
screen
circul
ctl
virusinfect
individu
thoma
et
al
recent
demonstr
tcell
immunodomin
hierarchi
may
depend
concentr
present
epitop
size
avail
tcell
repertoir
activ
initi
prime
competit
cooper
differ
epitopespecif
respons
addit
zhong
et
al
compar
motifpredict
method
direct
mass
spectrometri
analysi
endogen
present
epitop
isol
virusinfect
cell
use
larg
number
natur
process
vivopres
viral
ctl
epitop
mous
model
system
studi
reveal
high
number
predict
epitop
process
present
infect
cell
complex
tcellbas
screen
function
epitop
approach
may
miss
hidden
subdomin
epitop
therefor
advantag
work
revers
use
empir
approach
identifi
natur
present
hlaassoci
tcell
epitop
end
product
mhc
class
process
peptid
stimul
ctl
verifi
present
infect
cell
avail
recognit
vivo
ctl
activ
vaccin
last
decad
direct
identif
mhc
class
ipres
epitop
infect
cell
emerg
altern
motifpredict
method
term
immunoproteom
one
challeng
methodolog
identif
infectionrel
peptid
among
major
nondiseas
peptid
deriv
cellular
protein
present
infect
cell
surfac
sever
strategi
develop
analyz
mhc
class
iassoci
peptid
apc
approach
gener
base
isol
mhcassoci
peptid
follow
mass
spectrometri
analysi
stabl
isotop
tag
method
also
develop
distinguish
viral
epitop
epitop
deriv
cellular
protein
although
immunogen
mhc
class
iassoci
viral
epitop
lessabund
speci
present
highli
complex
mixtur
directli
extract
peptid
stabl
isotop
tag
epitop
power
strategi
rapid
unambigu
identif
natur
process
present
epitop
induc
viral
infect
strateg
import
vaccin
develop
recent
sever
crossserotyp
conserv
denvspecif
mhc
class
iassoci
tcell
epitop
denvinfect
cell
crossstrain
conserv
influenza
epitop
report
laboratori
use
immunoproteom
approach
underlin
signific
feasibl
tcell
epitop
vaccin
develop
success
tcell
vaccin
must
deliv
system
capabl
induc
robust
peptidespecif
tcell
respons
virusinfect
cell
deliveri
system
must
appropri
size
rang
mimic
viral
particl
allow
uptak
well
includ
builtin
danger
signal
adjuv
target
apc
promis
deliveri
system
tcell
epitop
includ
gold
nanoparticl
liposom
viruslik
particl
shown
induc
effici
vaccin
respons
advantag
disadvantag
system
instanc
peptid
molecular
adjuv
tolllik
receptor
agonist
easili
incorpor
nanoparticl
liposom
chemic
mean
hand
viruslik
particl
would
requir
clone
target
antigen
use
mammalian
cell
cultur
system
synthes
viruslik
natur
would
offer
excel
adjuv
also
feasibl
incorpor
deliveri
system
current
vaccin
would
drive
tcell
immun
presenc
activ
proven
humor
respons
tcell
vaccin
field
infanc
ongo
earlystag
clinic
studi
relev
gener
peptid
vaccin
mani
advantag
consid
safe
easi
produc
stabl
regardless
epitop
identifi
sever
peptid
vaccin
develop
due
earli
success
anim
studi
feasibl
within
next
year
sever
therapeut
peptid
vaccin
chronic
viral
infect
market
exampl
peptid
vaccin
develop
includ
design
toward
cmv
hcv
hpv
hiv
therapeut
peptid
vaccin
hcv
intercel
current
clinic
trial
includ
four
highli
conserv
ctl
epitop
addit
three
mhc
class
ii
helper
epitop
upon
analysi
ctl
respons
chronic
infect
patient
would
seem
multival
howev
respons
weak
compar
acut
infect
present
treatment
chronic
hcv
infect
consist
combin
pegyl
interferon
ribavirin
margin
success
depend
toler
cost
fortun
progress
phase
ii
clinic
trial
promis
outlook
regard
immunogen
sustain
reduc
viral
load
chronic
hcvinfect
patient
first
signific
antivir
effect
peptid
vaccin
hcvinfect
patient
anoth
therapeut
peptidebas
vaccin
studi
hpv
lead
caus
cervic
cancer
focus
tcell
determin
deriv
two
oncoprotein
express
requir
transform
cervic
cell
recent
murin
studi
wu
colleagu
demonstr
mhc
class
peptid
addit
panmhc
class
ii
helper
peptid
agonist
effect
inde
intratumor
inject
formul
demonstr
better
surviv
effici
ctl
respons
sever
clinic
trial
underway
involv
ctl
epitop
helper
peptid
interestingli
peptid
vaccin
went
phase
ii
clinic
trial
made
known
epitop
overlap
long
peptid
cover
protein
inocul
formul
compris
peptid
montanid
seppic
adjuv
demonstr
strong
tcell
respons
addit
memori
develop
furthermor
vaccin
display
low
toxic
high
immunogen
demonstr
promis
efficaci
peptid
vaccin
formul
target
hiv
protein
also
develop
peptid
deriv
major
core
protein
gag
combin
gmcsf
adjuv
vaccin
term
bionor
pharma
norway
phase
ii
clinic
trial
demonstr
signific
immunogen
peptid
formul
addit
decreas
viral
burden
high
respond
fortun
viral
escap
mutant
measur
amino
acid
alter
postvaccin
patient
remain
low
furthermor
also
shown
elicit
effici
memori
respons
vaccinerecipi
display
strong
delayedtyp
hypersensit
reaction
year
immun
howev
anoth
ctl
multiepitop
vaccin
underw
phase
clinic
trial
display
weak
immunogen
six
volunt
gener
specif
respons
measur
elispot
assay
unfortun
peptid
plu
adjuv
alon
poorli
immunogen
although
peptid
deliv
natur
mechan
may
better
outcom
instanc
vaccin
develop
incorpor
peptid
deriv
envelop
glycoprotein
virosom
taken
togeth
peptid
vaccin
hiv
plausibl
immunogen
driven
major
determin
includ
peptid
adjuv
deliveri
system
recent
tcell
vaccin
base
peptidemap
technolog
atla
design
genocea
bioscienc
usa
enter
phase
clinic
studi
formul
includ
viral
antigen
well
novel
saponinderiv
adjuv
demonstr
strong
immunostimulatori
profil
thu
far
preclin
proofofconcept
studi
promis
illustr
protect
viral
diseas
addit
reduc
durat
sever
clinic
symptom
limit
vaccin
primarili
depend
tcell
epitop
without
complementari
subunit
compon
immun
evas
virus
mani
virus
immun
evas
strategi
rang
alter
amino
acid
sequenc
epitop
flank
residu
may
hinder
recognit
epitop
process
present
mutat
present
viral
genom
repres
anoth
mechan
viru
abolish
epitopebind
properti
mhc
molecul
caus
failur
gener
epitop
altogeth
addit
mutat
mani
virus
interfer
antivir
immun
respons
express
specif
molecul
inhibit
hinder
antigen
process
present
antigen
epitop
specif
immun
impair
controversi
one
antivir
respons
oligoclon
sever
experiment
studi
indic
epitopespecif
respons
inhibit
virusinduc
immun
evas
mechan
key
success
tcell
vaccin
gener
oligoclon
antivir
respons
overcom
viru
strategi
immun
evas
clear
vaccin
futur
requir
simpli
inactiv
pathogen
strain
fortun
technolog
progress
enough
allow
us
identifi
immunodomin
memoryinduc
peptid
present
mhc
class
molecul
virusinfect
cell
arm
peptid
vaccin
formul
incorpor
antigen
activ
humor
cellular
immun
variou
adjuv
drive
strong
immun
respons
high
immunogen
addit
use
peptid
offer
flexibl
simpl
way
synthes
vaccin
therefor
highli
like
peptid
vaccin
play
larg
part
overal
vaccin
strategi
offer
hope
univers
prophylact
well
therapeut
vaccin
protect
infect
therapi
chronic
infect
respect
tcell
vaccin
could
play
major
role
viral
infect
influenza
denv
antibodytarget
vaccin
limit
clinic
efficaci
due
signific
variat
envelop
protein
variou
strain
signific
effort
direct
find
conserv
region
envelop
protein
gener
broad
humor
immun
influenza
viru
sinc
current
convent
influenza
vaccin
gener
crossprotect
success
approach
especi
regard
conserv
antibodi
epitop
hemagglutinin
twoprong
humor
cellular
approach
like
go
best
option
addit
effort
aim
target
conserv
protein
within
viru
influenza
viru
nucleoprotein
sinc
antibodi
reach
protein
prevent
infect
peptid
deriv
intracellular
process
protein
present
context
mhc
class
molecul
must
util
concept
behind
approach
stimul
cell
quickli
kill
virusinfect
cell
cell
produc
new
virion
thu
limit
diseas
sever
vaccin
base
nucleoprotein
human
viru
shown
protect
anim
lethal
dose
bird
influenza
gener
increas
tcell
respons
healthi
adult
clinic
studi
vaccin
builtin
crosssubtyp
efficaci
could
prevent
signific
spread
emerg
reemerg
strain
crosssubtyp
vaccin
contain
immunogen
consensu
sequenc
epitop
could
achiev
goal
mount
evid
suggest
effici
univers
influenza
vaccin
must
induc
activ
cellmedi
immun
humor
immun
along
line
vaccin
base
defin
epitop
present
infect
cell
would
far
superior
viral
protein
subunit
motifpredict
epitopebas
vaccin
protein
process
immun
system
may
alter
nativ
viral
epitop
anoth
crossserotyp
vaccin
need
one
denv
earli
vaccin
studi
demonstr
tcell
respons
viru
larg
serotypespecif
may
suggest
level
present
mhc
class
ii
antigen
differ
among
serotyp
benefici
effect
vaccineinduc
respons
underscor
signific
tcell
respons
vaccin
develop
anoth
import
step
may
addit
peptid
vaccin
formul
current
clinic
trial
elicit
strong
humor
respons
poor
tcell
respons
recent
report
conserv
tcell
epitop
identifi
denvinfect
cell
direct
immunoproteom
analysi
denvinfect
cell
highlight
feasibl
tcell
vaccin
concept
well
establish
cellmedi
immun
respons
play
critic
role
combat
viral
infect
tcell
respons
elimin
virusinfect
cell
humor
respons
neutral
viru
vivo
improp
activ
cell
infect
shown
induc
patholog
effect
host
care
taken
consid
balanc
protect
pathogenesi
develop
tcell
vaccin
prophylact
vaccin
mimic
natur
immun
infect
gener
humor
cellmedi
adapt
immun
memori
univers
vaccin
viral
infect
dengu
influenza
achiev
antibodyinduc
vaccin
combin
tcell
vaccin
cellmedi
immun
respons
play
major
role
therapeut
vaccin
applic
elimin
chronic
infect
cell
bodi
crossstrain
conserv
tcell
epitop
essenti
therapeut
vaccin
chronic
infect
hbv
hcv
hiv
cellmedi
immun
respons
gener
conserv
antigen
epitop
crucial
viral
infect
dengu
influenza
variat
viral
envelop
protein
common
ident
tcell
epitop
present
mhc
class
molecul
infect
cell
essenti
develop
tcell
vaccin
tcell
epitopebas
vaccin
requir
effici
adjuv
epitopedeliveri
system
target
apc
method
identif
tcell
epitop
includ
overlap
peptid
analysi
motifpredict
algorithm
direct
immunoproteom
analysi
direct
identif
tcell
epitop
infect
cell
use
immunoproteom
advantag
compar
variou
method
use
field
major
advanc
made
gener
tcell
respons
peptid
immun
prophylact
therapeut
vaccin
applic
sever
therapeut
vaccin
infecti
diseas
includ
hbv
hcv
hiv
hpv
infect
clinic
test
preclin
earlystag
clinic
studi
conduct
tcell
epitopebas
vaccin
infect
includ
dengu
influenza
hsv
virus
develop
strategi
evad
tcell
immun
respons
develop
sever
mechan
includ
imped
antigen
process
epitop
present
express
immun
respons
inhibitori
molecul
report
induct
multiepitopespecif
tcell
respons
essenti
overcom
virusinduc
immun
evas
